Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations

Impact · against what's priced in

The publication provides academic validation for QTORIN's mechanism but primarily serves as a vehicle to reiterate the success of the Phase 3 SELVA trial. The significant upside remains tied to the potential for FDA approval in a market of 30,000 patients with no approved therapies.

PVLA+0.70

No priced-in read yet